» Articles » PMID: 2862166

The Control of Cancer Chemotherapy-induced Nausea and Vomiting

Overview
Date 1985 Jun 1
PMID 2862166
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The incidence and consequences of the nausea and vomiting induced by many cancer chemotherapeutic regimes are explored and the emetogenic potential of the commonly used cytotoxic drugs evaluated. The physiology and pharmacology of chemotherapy-induced vomiting is largely unresolved but the postulated mechanisms are described and related to known properties of anti-emetic agents. The difficulties associated with the design and evaluation of trials assessing the effectiveness of single agent or combination therapy for this indication are discussed. After identifying general principles of anti-emetic prophylaxis, a critical evaluation is made of the effectiveness of the following drugs or classes of drugs, based on the available data: antihistamines, anticholinergics, phenothiazines, butyrophenones, domperidone, metoclopramide, cannabinoids, corticosteroids and benzodiazepines. Although there are still insufficient data to allow absolute recommendations to be made regarding the choice of anti-emetic therapy, considerations which should govern drug choice are listed and an algorithm presented as an aid to decision making. The contributions that can be made by a pharmacist in this area of drug use are noted.

Citing Articles

Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal.

Dulal S, Paudel B, Neupane P, Shah A, Acharya B, Poudyal B J Glob Oncol. 2019; 5:1-6.

PMID: 31013182 PMC: 6528728. DOI: 10.1200/JGO.18.00245.


Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy.

Smith L, Azariah F, Lavender V, Stoner N, Bettiol S Cochrane Database Syst Rev. 2015; (11):CD009464.

PMID: 26561338 PMC: 6931414. DOI: 10.1002/14651858.CD009464.pub2.


Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update.

Aprile G, Rihawi K, De Carlo E, Sonis S World J Gastroenterol. 2015; 21(41):11793-803.

PMID: 26557003 PMC: 4631977. DOI: 10.3748/wjg.v21.i41.11793.


Pharmacokinetics of high-dose metoclopramide in cancer patients.

McGovern E, Grevel J, Bryson S Clin Pharmacokinet. 1986; 11(6):415-24.

PMID: 3542335 DOI: 10.2165/00003088-198611060-00001.


Acupuncture prophylaxis of cancer chemotherapy-induced sickness.

Dundee J, Ghaly R, Fitzpatrick K, Abram W, LYNCH G J R Soc Med. 1989; 82(5):268-71.

PMID: 2666662 PMC: 1292129. DOI: 10.1177/014107688908200508.